Avaya Holdings Corp. (AVYA) is now among the bigger bargains in its industry.
Within the last year the price ranged from $9.73 – 22.35 and there is a wide opportunity to get in. Its next earnings report will be released on Feb 10, 2020.
Y-mAbs Therapeutics, Inc.(YMAB)
move, based on 5 analysts offering 12 month price targets for Y-Mabs Therapeutics in the last 3 months. The average price target is $39.75 with a high forecast of $40.00 and a low forecast of $39.00. The average price target represents a 32.99% increase from the last price of $29.89.
Analysts like Anupam Rama from J.P. Morgan believe that we could see stock price minimum $39.00.
Another prominent analyst, Ram Selvaraju of H.C. Wainwright rates YMAB as a Buy. The rating was made just 2 months ago.
Y-mAbs Therapeutics, Inc.(YMAB) Recent News Reports
On average 0.0 articles are written each week about YMAB but this week 0 articles were written and they were 68% Bullish and 32% Bearish.
Y-mAbs Therapeutics, Inc. Target Levels
The market experts are predicting that YMAB is a Strong Buy. Some other stocks to consider in this sector are: